На этой странице перечислены больницы направления «Хирургическая онкология» (включая Melanoma Surgery) в Бангалор, Индия, включая Narayana Health, Manipal Hospitals, Medicover Hospital, Bangalore, Gleneagles Hospitals, Bengaluru и другие.
Спросите нас о «Melanoma Surgery» в Бангалор, Индия
Оставьте свои данные — наша команда координации свяжется с вами и расскажет о следующих шагах.
Сравните 10 аккредитованных больниц (Хирургическая онкология) в Бангалор, Индия
Рекомендуем🇮🇳 Narayana Health
Больница занимает 1-е место в этом списке по указанному рейтингу (4.8/5, 1750 отзывов).
🇮🇳 Manipal Hospitals
Больница занимает 2-е место в этом списке по указанному рейтингу (4.7/5, 1450 отзывов).
🇮🇳 Medicover Hospital, Bangalore
Больница занимает 3-е место в этом списке по указанному рейтингу (4.7/5, 68 отзывов).
🇮🇳 Gleneagles Hospitals, Bengaluru
Больница занимает 4-е место в этом списке по указанному рейтингу (4.7/5, 142 отзывов).
🇮🇳 Manipal Hospital Malleshwaram (Northside)
Больница занимает 5-е место в этом списке по указанному рейтингу (4.6/5, 71 отзывов).
🇮🇳 Manipal Hospital, Old Airport Road
Больница занимает 6-е место в этом списке по указанному рейтингу (4.5/5, 87 отзывов).
🇮🇳 Manipal Hospital Yeshwanthpur (Columbia Asia)
Больница занимает 7-е место в этом списке по указанному рейтингу (4.5/5, 98 отзывов).
🇮🇳 Manipal Hospital Millers Road (Vikram Hospital)
Больница занимает 8-е место в этом списке по указанному рейтингу (4.4/5, 74 отзывов).
🇮🇳 Apollo Hospital, Bannerghatta Road
Больница занимает 9-е место в этом списке по указанному рейтингу (4.2/5, 25 отзывов).
🇮🇳 Fortis Hospital, Bannerghatta Road
Больница занимает 10-е место в этом списке по указанному рейтингу (4.2/5, 58 отзывов).
Как мы выбираем эти больницы
Больница появляется на этой странице, если направление «Хирургическая онкология» указано среди её специализаций и она находится в Бангалор, Индия. Сортировка — по указанному рейтингу (по убыванию), без редакционного рейтинга «лучших».
Как выбрать лучшую больницу для «melanoma surgery» в Бангалор, Индия?
Выбор подходящей больницы для «melanoma surgery» — важное решение в вашем пути лечения. Вот на что стоит обратить внимание:
Международная аккредитация
Ищите больницу с международной аккредитацией, например JCI или NABH — см. отметки аккредитации у каждой больницы ниже.
Специализация
Убедитесь, что в больнице есть отделение, специализирующееся на «Хирургическая онкология», а не только общая помощь.
Мощность и опыт
Количество коек и год основания, указанные ниже, отражают масштаб и операционный опыт больницы.
Прозрачность стоимости
Запросите детализированную смету перед поездкой — используйте наш калькулятор стоимости для первичной оценки.
Что нужно знать о процедуре «Melanoma Surgery»
Melanoma surgery encompasses a spectrum of oncological procedures—from wide local excision and sentinel lymph node biopsy to radical lymphadenectomy and isolated limb perfusion—designed to achieve clear surgical margins and prevent systemic metastasis in patients diagnosed with cutaneous or mucosal melanoma. Across major cancer centers in India and the UAE, 5-year survival rates for Stage I and Stage II melanoma following definitive surgical resection exceed 90% and 65% respectively, with advanced adjuvant immunotherapy protocols further improving outcomes for higher-stage disease. GAF Healthcare connects international patients to JCI- and NABH-accredited institutions in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi, offering end-to-end oncology coordination, second-opinion facilitation, and cost-transparent treatment pathways for melanoma at a fraction of Western prices. Hospital Stay: 3–10 days (varies by stage: 3–5 days for wide local excision with SLNB; up to 10 days for radical lymphadenectomy or reconstructive flap surgery) • Total Stay in Country (Fit-to-Fly): 2–6 weeks (Stage I–II simple excision: 2–3 weeks; Stage III with lymph node dissection or reconstruction: 4–6 weeks; adjuvant therapy patients reviewed individually) • Success Rate: 90%+ (Stage I); 65–80% (Stage II); 40–60% (Stage III with adjuvant immunotherapy)
Clinical Overview
Melanoma is a malignancy arising from melanocytes—the pigment-producing cells found predominantly in the skin but also in the ocular uvea, mucous membranes, and meninges. Cutaneous melanoma accounts for approximately 1–2% of all skin cancers by incidence but is responsible for the overwhelming majority of skin cancer deaths, owing to its propensity for early lymphatic and hematogenous dissemination. The four principal histological subtypes—superficial spreading, nodular, lentigo maligna, and acral lentiginous melanoma—differ in growth pattern and anatomical predilection, but all share the capacity for vertical-phase invasion once Breslow thickness exceeds 1 mm or Clark level IV is reached. Key molecular drivers include mutations in BRAF (V600E in approximately 50% of cutaneous cases), NRAS, c-KIT, and NF1, which have reshaped both surgical planning and adjuvant systemic therapy selection. The physiological consequences of unresected melanoma extend well beyond the primary lesion. Regional lymph node involvement (Stage III) triggers immune cascade dysregulation, while distant metastases (Stage IV) most commonly colonize the lungs, liver, brain, and bone, causing organ-specific morbidity. The tumor microenvironment is characterized by high immunogenicity, which is why melanoma was the index cancer for modern immune checkpoint inhibitor therapy. Staging follows the AJCC 8th Edition TNM system, incorporating Breslow thickness, ulceration status, mitotic rate, satellite/in-transit lesions, and the number and burden of involved lymph nodes. Accurate staging drives surgical decision-making and determines eligibility for adjuvant pembrolizumab, nivolumab, or targeted BRAF/MEK inhibitor combinations (dabrafenib plus trametinib). The standard of care for resectable melanoma is surgical excision with histologically confirmed clear margins, the width of which is evidence-based: 0.5 cm for melanoma in situ, 1 cm for Breslow ≤1 mm, 1–2 cm for 1.01–2 mm thickness, and 2 cm for tumors >2 mm. Sentinel lymph node biopsy (SLNB) is recommended for tumors ≥0.8 mm or those with adverse features (ulceration, mitoses) to stage regional nodal basins without the morbidity of elective complete lymph node dissection. Completion lymph node dissection (CLND) is now selectively reserved based on the MSLT-II trial data and individual nodal tumor burden. Adjuvant systemic therapy post-surgery and radiation therapy for selected nodal or mucosal sites complete the multidisciplinary treatment framework practiced at top-tier centers in India and the UAE.
Who is a Candidate?
• ELIGIBLE PATIENTS: • Histologically confirmed melanoma at any AJCC stage (I–IV) where surgical resection is feasible with curative or cytoreductive intent • Patients with primary tumor Breslow thickness ≥0.8 mm or any thickness with ulceration or high mitotic rate requiring SLNB mapping • Stage III patients with clinically or biopsy-proven regional lymph node metastasis requiring therapeutic lymph node dissection (inguinal, axillary, or cervical) • Patients with oligometastatic Stage IV disease (isolated lung, adrenal, or subcutaneous metastases) suitable for metastasectomy combined with systemic immunotherapy • Patients with desmoplastic melanoma or acral lentiginous melanoma requiring wide margins and reconstructive flap or skin graft coverage • Patients seeking second opinions on margin adequacy or re-excision after prior incomplete resection • International patients who have completed initial biopsy and pathology abroad and require definitive surgical staging and treatment • REQUIRED PRE-OPERATIVE DIAGNOSTICS: • Dermatopathology review of primary biopsy with Breslow thickness, Clark level, ulceration status, mitotic rate, and perineural/lymphovascular invasion reporting • BRAF V600E/K mutation testing (ideally full BRAF/NRAS/NF1/c-KIT panel via next-generation sequencing) for all Stage IIB and above • Whole-body PET-CT scan (18F-FDG) for Stage IIB–IV staging and detection of occult nodal or distant metastases • MRI brain with gadolinium contrast for Stage III–IV to exclude cerebral metastases • Lymphoscintigraphy with dynamic planar imaging and SPECT-CT for sentinel lymph node mapping of the draining nodal basin prior to SLNB • Complete blood count, comprehensive metabolic panel, LDH (elevated LDH is an independent poor prognostic marker in Stage IV) • CT chest/abdomen/pelvis with contrast as an alternative staging workup where PET-CT is not available • Baseline ECHO and pulmonary function tests for patients planned for adjuvant immunotherapy or isolated limb perfusion • CONTRAINDICATIONS & CAUTIONS: • Unresectable Stage IV disease with high systemic burden where first-line systemic immunotherapy (anti-PD-1 ± anti-CTLA-4) should precede surgical consideration • Severe cardiac or pulmonary comorbidities precluding general anesthesia (individualized risk assessment by anesthesiology team required) • Active autoimmune conditions (relative contraindication to concurrent immunotherapy, not to surgery itself) • Coagulopathies or anticoagulation regimens requiring perioperative bridging management • Pregnancy (requires multidisciplinary maternal-fetal medicine consultation; surgery may proceed in selected cases)
Treatment Options & Approaches
STANDARD SURGICAL APPROACHES: • Wide Local Excision (WLE): The cornerstone of melanoma surgery. The primary lesion is excised en bloc with a margin of normal tissue calibrated to Breslow thickness per NCCN/ESMO guidelines (0.5–2 cm). Performed under local or regional anesthesia for thin lesions; general anesthesia for deeper tumors or complex anatomical sites (face, hands, feet, mucosa). Wound closure may be primary, or may require split-thickness skin grafting (STSG) or local rotational flaps where primary closure would compromise function or result in unacceptable deformity. • Sentinel Lymph Node Biopsy (SLNB): The standard staging procedure for intermediate and thick melanomas. Dual-agent lymphatic mapping uses a combination of technetium-99m-labeled nanocolloid (injected the day prior with lymphoscintigraphy/SPECT-CT mapping) and intraoperative Patent Blue V or isosulfan blue dye injection at the primary site. The gamma probe identifies the hot sentinel node(s) for targeted excision with minimal morbidity. Alternatively, fluorescence-guided SLNB using indocyanine green (ICG) with near-infrared imaging is offered at advanced centers in India and the UAE, improving real-time intraoperative nodal visualization. • Therapeutic Lymph Node Dissection (TLND): Indicated for clinically or radiologically involved regional lymph nodes. Axillary dissection (Levels I–III), inguinofemoral dissection (superficial ± deep iliac/obturator nodal clearance based on Cloquet's node status), and radical neck dissection (modified or selective) are performed. Based on MSLT-II and DeCOG-SLT trial data, immediate CLND following a positive SLNB is no longer routine; it is reserved for patients with high nodal tumor burden or extracapsular extension. • Isolated Limb Perfusion (ILP) and Isolated Limb Infusion (ILI): For unresectable in-transit or satellite metastases confined to a limb. ILP uses a pump oxygenator to deliver high-dose melphalan (±TNF-alpha) via hyperthermic perfusion of the isolated limb vasculature, achieving locoregional drug concentrations 15–25 times higher than systemic delivery. ILI is a simpler catheter-based variant available at specialized centers. Complete response rates of 25–35% and overall response rates of 60–80% are reported. • Reconstructive Surgery: Complex resections involving the face, scalp, digits, or plantar surface require concurrent oncoplastic reconstruction. Techniques include: pedicled or free myocutaneous flaps (anterolateral thigh flap, radial forearm free flap), tissue expansion, and digit reconstruction. India's major oncology centers house dedicated plastic and reconstructive surgery teams with high-volume melanoma reconstruction experience. ADVANCED & MINIMALLY INVASIVE MODALITIES: • Robotic-Assisted Lymphadenectomy: Available at select centers in India (Medanta, Fortis, Apollo) and the UAE (Cleveland Clinic Abu Dhabi, American Hospital Dubai). Robotic platforms (da Vinci Xi) enable inguinal and pelvic lymphadenectomy via smaller incisions, improving visualization in deep anatomical compartments and reducing postoperative lymphedema compared to open approaches, though open surgery remains the standard for complex dissections. • Mohs Micrographic Surgery (MMS): Used selectively for lentigo maligna melanoma (melanoma in situ) of the face and acral sites where tissue conservation is critical. Staged excision with intraoperative margin assessment via rush permanent sections (slow Mohs technique) is preferred over true Mohs for invasive melanoma to allow complete vertical and radial margin evaluation. • Stereotactic Radiosurgery (SRS) / CyberKnife for Brain Metastases: For oligo-metastatic Stage IV patients with 1–4 brain metastases, SRS (Gamma Knife, CyberKnife) delivers ablative radiation doses with sub-millimeter precision, avoiding the neurocognitive toxicity of whole-brain radiation therapy (WBRT). Available at Tata Memorial, HCG, and AIIMS in India, and at Burjeel Medical City and American Hospital Dubai in the UAE. • Electrochemotherapy (ECT): An emerging modality combining bleomycin injection with reversible electroporation to enhance drug uptake in cutaneous and subcutaneous melanoma metastases, available at select oncology centers as a palliative or bridging treatment. ADJUVANT SYSTEMIC THERAPIES (Surgical Context): • BRAF V600-mutant patients (Stage IIB–III): Adjuvant dabrafenib + trametinib for 12 months post-resection reduces relapse risk by ~50%. • BRAF wild-type and all resected Stage III–IV: Adjuvant pembrolizumab (anti-PD-1, 200 mg Q3W × 12 months) or nivolumab (240 mg Q2W × 12 months) per KEYNOTE-716 and CheckMate 238 data. • Adjuvant ipilimumab (anti-CTLA-4) is available but has a less favorable toxicity profile and is increasingly superseded by anti-PD-1 monotherapy.
Восстановление
PHASE 1 — PRE-ARRIVAL & CONSULTATION (Weeks 1–3 before travel): • GAF Healthcare receives patient's biopsy pathology report, imaging (PET-CT, MRI brain), and mutation profiling results for virtual multidisciplinary tumor board review. • Case is presented to a senior surgical oncologist (melanoma specialist) and a medical oncologist at the selected partner hospital. • A written second opinion and treatment plan (surgical approach, reconstruction requirements, adjuvant therapy recommendation) is issued within 5–7 business days. • GAF Healthcare assists with e-Medical Visa application (India) or UAE entry visa coordination. Hospital invitation letters and visa documentation provided within 48 hours of plan confirmation. • Pre-travel instructions issued: medications to withhold (anticoagulants, aspirin 7–10 days pre-op), dietary guidance, compression stockings for DVT prophylaxis during long-haul flight. PHASE 2 — ARRIVAL & PRE-OPERATIVE WORKUP (Days 1–3 in-country): • Airport transfer by GAF Healthcare's dedicated medical concierge team. • Day 1: Oncology outpatient consultation, clinical examination of primary lesion and regional lymph node basins, review of all external investigations. • Day 2: Any required in-house investigations (repeat PET-CT if >8 weeks old, ECHO, pulmonary function tests, full blood workup, anesthesiology pre-assessment). Lymphoscintigraphy performed for SLNB mapping if SLNB is planned. • Day 3: Surgical consent process (interpreter-assisted), marking of excision margins, pre-operative skin preparation. Admission to surgical ward. Anesthesia review and optimization. PHASE 3 — SURGERY (Day 4 or 5): • Wide Local Excision: Typically 1–3 hours under general or regional anesthesia. Intraoperative frozen section margin assessment where anatomically feasible. Wound closure or graft/flap reconstruction performed in the same operative session. • SLNB Addition: Adds 30–60 minutes. Gamma probe and blue dye guidance; sentinel nodes sent for permanent section histopathology (results in 3–5 days) and immunohistochemistry (S-100, HMB-45, Melan-A). • Lymph Node Dissection (if planned as primary procedure): 2–5 hours depending on basin and extent. • Isolated Limb Perfusion: 4–6 hours including cannulation, perfusion circuit establishment, and decannulation. PHASE 4 — IMMEDIATE POST-OPERATIVE RECOVERY (Days 5–10 in hospital): • Day 1 post-op: Monitoring in surgical HDU or ICU (ILP patients); pain management with multimodal analgesia; DVT prophylaxis with low-molecular-weight heparin resumed 24–48 hours post-operatively. • Day 2–3: Ambulation initiated; wound drains output monitored; soft diet resumed; lymphedema prophylaxis education for patients undergoing nodal dissection. • Day 4–5: Drain removal when output <30 mL/24 hours; graft inspection and dressing change; dermatology and wound care team review. • Day 5–7 (simple WLE ± SLNB): Discharge from hospital to hotel/accommodation. SLNB histopathology results reviewed with surgical oncologist; adjuvant therapy plan confirmed if node-positive. • Day 8–10 (lymph node dissection or flap reconstruction): Discharge when wound is stable and patient demonstrates adequate self-care of wound site. PHASE 5 — POST-DISCHARGE RECOVERY IN DESTINATION (Until Fit to Fly): • Week 2: Outpatient wound review, suture removal (or confirmation of absorbable suture integrity); compression garment fitting for limb lymphedema prevention; first post-operative oncology consultation. • Week 3: Final surgical oncologist clearance for international travel. For patients commencing adjuvant immunotherapy (pembrolizumab/nivolumab), Cycle 1 may be administered before departure if patient and oncologist agree; subsequent cycles can be administered in home country with GAF Healthcare-facilitated records transfer. • Fit-to-Fly Milestones: Wound healed without dehiscence; no active infection; drain-free; DVT risk acceptable (compression stockings + LMWH or DOAC for long-haul flight); no active immunotherapy-related adverse events requiring on-site management. PHASE 6 — LONG-TERM FOLLOW-UP PROTOCOL: • Surveillance: Dermatology examination every 3 months for 2 years, then every 6 months for 3 years, then annually. • Imaging: CT chest/abdomen/pelvis or PET-CT every 6 months for 3 years (Stage III–IV). • GAF Healthcare provides telemedicine follow-up coordination between the treating surgeon in India/UAE and the patient's home oncologist; translated records and imaging CDs dispatched with patient on discharge.
Возможные риски
Melanoma surgery is generally well-tolerated, but patients and their families must be counseled on procedure-specific and stage-specific risks with full transparency. For wide local excision, the principal concerns are wound dehiscence (particularly over joints or following skin grafting), hematoma formation (1–3%), wound infection (2–5%), and graft failure requiring revision in 5–10% of reconstructed sites. Sentinel lymph node biopsy carries a false-negative rate of approximately 5–10%, meaning a negative SLNB does not guarantee absence of nodal micrometastasis; it also carries a small risk of lymphedema (<5%), seroma, and neurosensory changes at the biopsy site. Completion or therapeutic lymph node dissection carries significantly higher lymphedema risk—up to 30–40% for inguinofemoral dissections—along with wound breakdown in the groin (a notoriously challenging healing environment), deep vein thrombosis, and injury to adjacent neurovascular structures (femoral nerve, saphenous vein). Isolated limb perfusion (ILP) is associated with regional toxicity (limb erythema, blistering, compartment syndrome in 1–3%), systemic leak of melphalan causing transient bone marrow suppression, and, rarely, limb loss (<1%). Reconstructive flap surgery introduces risks of partial or total flap failure, donor site morbidity, and prolonged recovery. From an oncological perspective, the primary risk is inadequate surgical margin, which mandates re-excision and is associated with higher local recurrence rates. Patients with Stage III disease undergoing surgery face a 5-year relapse risk of 40–70% without adjuvant therapy, underscoring the importance of prompt initiation of pembrolizumab, nivolumab, or BRAF/MEK inhibitor therapy post-resection. Adjuvant immunotherapy itself introduces immune-related adverse events (irAEs)—colitis, pneumonitis, hepatitis, endocrinopathies—in 15–30% of patients, requiring proactive monitoring and, when severe, systemic corticosteroids. GAF Healthcare ensures all patients are comprehensively informed of these risks through pre-operative counseling sessions with both the surgical oncologist and a dedicated medical coordinator.
Почему GAF Healthcare
GAF Healthcare provides a fully integrated non-medical support framework to ensure that international patients experience zero logistical friction from the moment of inquiry to post-treatment repatriation. INDIA — VISA & ENTRY: GAF Healthcare facilitates the e-Medical Visa (eMV) application for India, which allows a stay of up to 60 days (extendable) and covers the patient plus one accompanying attendant on a Medical Attendant Visa. Required documents—hospital invitation letter, treatment cost estimate, valid passport, and passport-size photographs—are prepared by our team and submitted through the Indian government's online portal, with typical approval in 3–5 business days. Airport meets-and-greet with a dedicated GAF coordinator is arranged at all major Indian hubs (Delhi IGI, Mumbai CSIA, Chennai, Bengaluru, Hyderabad). UAE — VISA & ENTRY: Citizens of over 50 countries (EU, UK, USA, Canada, GCC nationals) receive visa-free or visa-on-arrival access to the UAE for 30–90 days, making it the most frictionless destination for medical travel. For patients requiring a Medical Visit Visa, GAF Healthcare coordinates the application through the UAE partner hospital's international patient services desk (IPS), which is a DHA-approved facilitator. Entry to Dubai (DXB/DWC) and Abu Dhabi (AUH) is typically granted within 48–72 hours. AIRPORT & GROUND TRANSFERS: All patients are received at the airport by a GAF-assigned medical escort or concierge representative. Wheelchair assistance, porter services, and air-conditioned private vehicle transfers to the hospital or accommodation are arranged in advance. Return airport transfers following discharge are likewise coordinated. MEDICAL INTERPRETATION & TRANSLATION: GAF Healthcare provides certified medical interpreters in Arabic, Russian, French, Swahili, Bangla, Uzbek, and other languages. Interpreters accompany patients to all consultations, surgical consent sessions, and post-operative reviews. All hospital discharge summaries, pathology reports, operative notes, and imaging CDs are provided in English plus the patient's native language upon request. ATTENDANT ACCOMMODATION & PATIENT SUPPORT: For patients accompanying an attendant (family member or nurse), GAF Healthcare pre-books serviced apartments or hotel rooms within 500 meters of the treating hospital, priced across a range of budgets. In-hospital attendant cot/recliner arrangements are coordinated with the ward team. Meal preferences, dietary restrictions, and prayer/religious requirements are communicated to the hospital's international patient services team in advance. TELEMEDICINE & POST-DEPARTURE CONTINUITY: Upon discharge, each patient is assigned a GAF Healthcare case manager who remains accessible for 12 months. All medical records are digitized and shared via a secure patient portal. GAF coordinates remote follow-up consultations with the treating oncologist via video call, facilitates prescription renewal for adjuvant therapies, and liaises with the patient's home oncologist for seamless continuity of care.
Частые вопросы о процедуре «Melanoma Surgery»
What is the cost of Melanoma Surgery in India compared to the UAE?
How long do I need to stay in India or the UAE before I am fit to fly home after Melanoma Surgery?
What is the success rate of Melanoma Surgery, and what factors affect long-term outcomes?
Похожие страницы
Как GAF Healthcare помогает выбрать лучшую больницу для «melanoma surgery» в Бангалор, Индия
Найдите лучшие больницы для «melanoma surgery» в Бангалор, Индия
На этой странице представлено 10 больниц в Бангалор, Индия, чтобы вы могли сравнить аккредитацию и специализации в одном месте.
Поддержка, когда она нужна
Отправьте нам свои медицинские отчёты в WhatsApp или по email — наша медицинская команда изучит их и предложит больницу и план лечения.
Прозрачные, всё включено цены
Мы предоставляем единую детализированную смету, покрывающую расходы больницы и проживание — без скрытых платежей.
Организация визы, поездки и проживания
После выбора больницы мы помогаем оформить визовое приглашение, забронировать проживание рядом с больницей и организовать трансфер.
Хотите узнать примерную стоимость лечения? Используйте наш калькулятор стоимости для персональной оценки.
Частые вопросы о «Melanoma Surgery» в Бангалор, Индия
Сколько больниц направления «Хирургическая онкология» представлено в Бангалор, Индия?
Как вы выбираете больницы для списка?
Сколько стоит лечение в Бангалор, Индия?
Следующий шаг
Отправьте нам свои медицинские отчёты — наша команда предложит больницу и план лечения для «Melanoma Surgery» в Бангалор, Индия.
Свяжитесь с нами, если заметите неточность на этой странице.